# Exkivity (mobocertinib succinate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mobocertinib

> The FDA approved Exkivity (mobocertinib succinate), sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), on September 15, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Exkivity (mobocertinib succinate) |
| Codes | TAK-788, AP32788 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/advanced-metastatic-non-small-cell-lung-cancer-nsclc) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### September 15, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215310 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210915, review_priority PRIORITY; sponsor_name TAKEDA PHARMS USA; product EXKIVITY (MOBOCERTINIB SUCCINATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215310%22

### September 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04129502 (TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04129502

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04129502 (TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT04129502

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mobocertinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Exkivity (mobocertinib succinate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mobocertinib

```bibtex
@misc{secapidev_pdufa_mobocertinib_20261116,
  title        = {Exkivity (mobocertinib succinate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mobocertinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mobocertinib_20261116","title":"Exkivity (mobocertinib succinate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mobocertinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
